# Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

> **NCT06859684** · PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma (Icc)
- HAIC
- Durvalumab

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** hepatic arterial infusion chemotherapy (HAIC)
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06859684
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2026-09-06
- **Final completion:** 2027-03-06
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06859684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06859684, "Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06859684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*